In collaboration with analysts from Datamonitor's Healthcare business unit, in this brief Ovum's Pharmaceutical Technology team outlines the key changes in the pharma industry, explains which trends will have the biggest impact, and analyses the implications and opportunities of these developments for both pharmaceutical companies and providers of technologies and services.
Scope
* This brief outlines business issues and technology enablers that are expected to affect the pharmaceutical industry during 2010.
* The report covers developments in North America and Europe.
Highlights
Through research and analysis, Ovum has identified several key trends that will shape the pharma and biotech markets in 2010. Pharma is evolving towards a new business model: Pharma 2.0, new R&D models embrace biotechnology and biomedical research and the future success of pharma relies on the emerging markets.
As the life sciences industry moves into its next phase, technology will play a significant role in its transformation. However, in the short term, there will be some solutions that will take precedence over others.
Reasons to Purchase
* Understand the key operational trends to watch during 2010.
* Gain insight into the technologies that pharmaceutical companies must either invest in or extract more value from in 2010.
For more information or to purchase this report, go to:
- http://www.fastmr.com/
Report Table of Contents:
Overview
CATALYST
SUMMARY
OVUM VIEW
analysis
BUSINESS TRENDS AND TECHNOLOGY ENABLERS
PHARMA IS EVOLVING TOWARDS A NEW BUSINESS MODEL: PHARMA 2.0
Innovative R&D marries business process with technology
New sales and marketing models focus on engaging with all stakeholders
External collaboration on R&D will enhance drug discovery
NEW R&D MODELS EMBRACE BIOTECHNOLOGY AND BIOMEDICAL RESEARCH
M&A helps biotech companies survive the funding crisis
Governments support biotech research
THE FUTURE SUCCESS OF PHARMA RELIES ON THE EMERGING MARKETS
The emerging markets provide ample M&A opportunities, but tread carefully
Outsourcing is a crucial strategy for making the Pharma 2.0 company leaner
ACTIONS
TECHNOLOGY RECOMMENDATIONS FOR ORGANISATIONS IN THE LIFE SCIENCES SECTOR
Streamline R&D operations by breaking down silos and increasing internal communication
Collaborate and partner with non-traditional stakeholders
Be creative in developing new sales and marketing strategies
RECOMMENDATIONS FOR PROVIDERS OF TECHNOLOGIES AND SERVICES
Educate life sciences companies on the benefits of pharma-specific commercial IT solutions
Cater to the emerging markets in order to see rapid growth
Focus on technology solutions that enable the shift towards personalised medicine
APPENDIX
DEFINITIONS
METHODOLOGY
FURTHER READING
LEAD AUTHOR
CONTRIBUTING AUTHOR
OVUM CONSULTING
DISCLAIMER
List of Figures
Figure 1: The evolution of the traditional pharma model to Pharma 2.0
Figure 2: The pharma product lifecycle aligning business processes with technology solutions
Figure 3: The underlying need for collaboration across the pharma lifecycle and where IT fits in
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
